目的：探讨利福喷丁与利福平在肺结核治疗中的药效及安全性。方法选取2014年6月～2016年6月来我所就诊的肺结核患者150例，其中使用利福喷丁治疗者75例，使用利福平治疗者75例，两组患者均治疗半年后，对比分析其治疗效果及用药不良反应。结果经过半年的治疗之后，利福喷丁组的痰液细菌学检查转阴率、病变吸收率、空洞闭合率、治疗有效率略高于利福平组，差异无统计学意义（P ＞0.05）；利福喷丁组的不良反应发生率显著低于利福平组，差异具有统计学意义（P ＜0.05）。结论利福喷丁在治疗肺结核方面疗效显著，不良反应率低，具有较高的临床价值，值得推广。%Objective To investigate the efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis from June 2014 to June 2016. Methods 150 cases of patients with pulmonary tuberculosis from our center were selected as the study objects. including 75 cases with rifapentine therapy, 75 cases with rifampicin treatment. Six months after the therapy, the therapeutic effect and adverse drug reaction of the two groups were compared and analyzed. Results After six months of treatment, the sputum bacteriology negative rate, lesions absorption rate and cavity closure rate, the effective rate of the rifapentine group were slightly higher than those of rifampicin group, and the difference was not statistically significant (P > 0.05). The adverse reaction rate of rifapentine group rifapentine group was significantly lower than that in rifampicin group, the difference was statistically significant (P < 0.05). Conclusion The curative effect of rifapentine in the treatment of pulmonary tuberculosis is significant. The adverse reaction rate is low, and it has high clinical value. It is worthy of promotion.
展开▼
